Background
The assessment of MGMT promoter methylation is essential for determining the appropriate therapy for glioblastoma. However, prior studies have primarily focused on intratumoral regions, neglecting the peritumoral area. This study aimed to develop a radiomic model utilizing features from both intratumoral and peritumoral regions derived from MRI images.
Methods
The study included 96 glioblastoma patients who were randomly divided into training and testing sets. Radiomic features were extracted from both tumor and peritumor regions. We constructed radiomic models based on intratumoral, peritumoral, and combined features for comparison. The models were evaluated using the area under the receiver-operator characteristic (ROC) curve (AUC).
Results
The combined radiomic model achieved an AUC of 0.814 (95% confidence interval: 0.767–0.862) in the training set and 0.808 (95% confidence interval: 0.736–0.859) in the testing set, surpassing the performance of models based solely on intratumoral or peritumoral features. Additionally, calibration and decision curves indicated excellent model fit and clinical utility.
Conclusions
The radiomics model incorporating both intratumoral and peritumoral features shows promise in differentiating MGMT status, which can inform clinical treatment strategies for glioblastoma.